Diterpene Glycosides from Fructus Rubi as Multitarget Modulators in DHT-Induced Benign Prostatic Hyperplasia

Study Background and Research Question

Benign prostatic hyperplasia (BPH) is a prevalent urological disorder characterized by nonmalignant prostate enlargement, often leading to lower urinary tract symptoms in aging males. Central to BPH pathogenesis is the androgen signaling axis, particularly the effects of dihydrotestosterone (DHT) on prostatic epithelial and stromal cell proliferation. DHT, a potent androgen receptor (AR) agonist, enhances proliferation and survival signaling in prostate tissue, with downstream effects mediated via pathways such as TGF-β/Smad. Despite the clinical utility of 5α-reductase inhibitors in BPH, treatment resistance and incomplete efficacy motivate the search for alternative or adjunctive molecular interventions. The recent study by Yu et al. addresses whether diterpene glycosides extracted from Fructus Rubi (FDS) can suppress BPH by modulating androgen and TGF-β/Smad pathways in DHT- and testosterone propionate (TP)-induced models.

Key Innovation from the Reference Study

The core innovation of this research lies in demonstrating that FDS, a standardized extract of diterpene glycosides from Fructus Rubi, exerts multitargeted inhibition of BPH through two distinct but interconnected pathways: androgen receptor signaling and TGF-β/Smad signaling. Notably, the study provides the first evidence that FDS can simultaneously downregulate DHT-mediated pro-proliferative and pro-fibrotic signals while promoting epithelial marker expression. This dual action sets FDS apart from monotherapeutic approaches that target only androgen or TGF-β signaling, suggesting a broader therapeutic window and potential for combinatorial strategies.

Methods and Experimental Design Insights

The researchers employed a robust two-pronged experimental design. First, human prostatic epithelial RWPE-1 cells were exposed to DHT to model androgen-driven hyperplasia in vitro. Second, BPH was induced in rats via subcutaneous injection of testosterone propionate, a strategy that increases both local and systemic DHT. FDS was administered orally to rats for 28 days, paralleling the clinical context of chronic phytotherapeutic intervention.

Target engagement and pathway analysis were addressed using drug affinity responsive target stability (DARTS) combined with mass spectrometry to identify FDS-interacting proteins. The study quantified DHT levels in serum and prostate tissue via ELISA, while cell proliferation, epithelial-mesenchymal transition (EMT), and pathway activation were evaluated through western blotting, immunohistochemistry, and immunofluorescence for key biomarkers: AR, PSA, SRD5A2, PCNA, S100A2, TGF-β1, E-cadherin, vimentin, and Smad4.

Protocol Parameters

• DHT induction (cell model): RWPE-1 cells treated with DHT to promote proliferation and AR signaling.
• BPH induction (animal model): Testosterone propionate subcutaneously injected in rats to elevate DHT and induce BPH over 28 days.
• FDS administration: Oral dosing of diterpene glycoside extract daily for 28 days in BPH rats.
• Pathway assessment: Protein and mRNA levels of AR, TGF-β1, Smad4, PCNA, E-cadherin, S100A2, PSA by WB, IHC, and IF for mechanistic dissection.
• DHT quantification: ELISA-based measurement in serum and prostate tissue to confirm hormonal modulation.

Core Findings and Why They Matter

Yu et al. report that FDS treatment significantly reduced proliferation of DHT-induced RWPE-1 cells and abrogated prostate enlargement in TP-induced BPH rats. Mechanistically, FDS decreased DHT levels in both serum and prostate, correlating with suppressed AR, PSA, PCNA, S100A2, TGF-β1, and Smad4 expression, while upregulating E-cadherin. This selective modulation suggests that FDS not only disrupts androgen-driven proliferation but also prevents EMT—a process implicated in tissue remodeling and fibrosis—through S100A2-mediated TGF-β/Smad signaling (see reference).

These findings are significant for several reasons. First, they validate the multitarget activity of FDS in both hormone- and growth factor-driven BPH pathogenesis, addressing a clinical need for broader mechanism coverage. Second, by demonstrating the capacity to modulate both AR and TGF-β/Smad axes, FDS may reduce the likelihood of treatment escape via compensatory pathway activation. Finally, the observed increase in E-cadherin—a marker of epithelial integrity—indicates a protective effect against EMT and fibrosis, which are key contributors to chronic BPH progression.

Comparison with Existing Internal Articles

Several recent analyses have described the mechanistic role of DHT in cancer and neurodegeneration models, emphasizing its utility in dissecting androgen receptor and growth factor signaling dynamics. For instance, the article "Dihydrotestosterone (DHT) in Cancer Signaling and Resistance Models" details how DHT enables precise interrogation of AR and EGFR/ERBB2 pathways in advanced malignancies, while "Dihydrotestosterone (DHT): Pathway Modulation and Translational Impact" focuses on cross-talk between androgen and EGFR signaling in translational research. Although these works address cancer rather than BPH, they reinforce the relevance of DHT as a molecular probe for androgen receptor signaling and downstream effectors such as AKT and ERK1/2 phosphorylation.

The present study extends these insights to benign disease, showing that modulation of DHT-driven pathways is equally critical in non-malignant hyperplasia and that plant-derived diterpene glycosides can effect broad pathway suppression. This highlights a translational continuum from cancer biology to BPH research, with androgen receptor and TGF-β/Smad signaling as central nodes.

Limitations and Transferability

While the dual-target inhibition observed with FDS is promising, several limitations merit consideration. The study primarily uses rodent models and immortalized human cell lines, which may not fully recapitulate the multicellular and endocrine complexity of human BPH. The extract's specific diterpene glycoside constituents were not individually characterized in functional assays, leaving open questions about the relative contribution of each component. Furthermore, long-term safety and efficacy in human populations remain to be demonstrated.

Transferability to clinical BPH should thus be approached cautiously, with the need for further profiling of FDS pharmacokinetics, off-target effects, and combinatorial potential with established therapies. Despite these caveats, the mechanistic framework provided by this study supports further translational investigation.

Research Support Resources

For researchers aiming to model androgen receptor signaling, EGFR pathway cross-talk, or to replicate DHT-driven hyperplastic processes in vitro and in vivo, Dihydrotestosterone (DHT) (SKU B8214, APExBIO) is available as a high-quality reagent. DHT is essential for inducing androgenic responses in prostate cell lines and animal models, supporting studies on AR, EGFR, and ERBB2 signaling, as highlighted in both the reference study and related oncology workflows. For protocol suggestions and troubleshooting, see internal resources such as DHT in Cancer Signaling and DHT Pathway Modulation. When using DHT, follow manufacturer guidelines for solubility, storage, and experimental dosing to ensure reproducibility and validity of results.